The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G

Basic and Clinical Pharmacology and Toxicology

Volumn 118, Issue 5, 2016, Pages 333-337

  Kodawara, Takaaki ^a   Higashi, Takashi ^a   Negoro, Yutaka ^a   Kamitani, Yukio ^a   Igarashi, Toshiaki ^a   Watanabe, Kyohei ^a   Tsukamoto, Hitoshi ^a   Yano, Ryoichi ^a   Masada, Mikio ^b   Iwasaki, Hiromichi ^a   Nakamura, Toshiaki ^a  

^a UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA GLUCURONIDASE; CIPROFLOXACIN; ENOXACIN; FIRTECAN; FIRTECAN GLUCURONIDE; GATIFLOXACIN; IRINOTECAN; LEVOFLOXACIN; PHENOLPHTHALEIN; PHENOLPHTHALEIN BETA DEXTRO GLUCURONIDE; STREPTOMYCIN; UNCLASSIFIED DRUG; 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONIDE;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EFFECT; IC50; IN VITRO STUDY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENTEROHEPATIC CIRCULATION; METABOLISM; TIME FACTOR;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROHEPATIC CIRCULATION; GLUCURONIDASE; GLUCURONIDES; TIME FACTORS;

EID: 84962744324     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12511     Document Type: Article

References (19)

1. Douillard JY. Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. Clin Colorectal Cancer 2005;5(Suppl 1):S34-7.
2. Kawahara M. Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations. Expert Opin Drug Saf 2006;5:303-12.
3. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:723-35.
4. Rivory LP, Robert J. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995;36:176-9.
5. Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 1993;23:5-10.
6. Kodawara T, Masuda S, Yano Y, Matsubara K, Nakamura T, Masada M. Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. Biopharm Drug Dispos 2014;35:275-83.
7. Bergmeyer HU. Methods of Enzymatic Analysis, Vol II, 2nd edn. Academic Press, New York NY, 1974;930-2.
8. Kim DH, Jin YH, Jung EA, Han MJ, Kobashi K. Purification and characterization of beta-glucuronidase from Escherichia coli HGU-3, a human intestinal bacterium. Biol Pharm Bull 1995;18:1184-8.
9. Guo W, Ahmad A, Khan S, Dahhani F, Wang YF, Ahmad I. Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38). J Chromatogr B Analyt Technol Biomed Life Sci 2003;791:85-92.
10. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010;330:831-5.
11. Roberts AB, Wallace BD, Venkatesh MK, Mani S, Redinbo MR. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 2013;84:208-17.
12. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991;21:1159-69.
13. Ahmad S, Hughes MA, Yeh LA, Scott JE. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors. J Biomol Screen 2012;17:957-65.
14. Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT et al. Old drug new use-amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res 2014;20:3521-30.
15. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80.
16. Sakata Y, Suzuki H, Kamataki T. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11). Gan To Kagaku Ryoho 1994;21:1241-4.
17. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003;51:403-6.
18. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991;83:1164-8.
19. Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992;84:972-4.